Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database.

ABSTRACT:

Objective

Zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor that has been approved for the treatment of several B cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on the real-world data.

Design

A disproportionality analysis was performed to identify the potential zanubrutinib-related AEs.

Setting

The Food and Drug Administration AE Reporting System database from the fourth quarter of 2019 to the third quarter of 2023.

Main outcome measures

The results of the disproportionality analyses were presented as reported ORs (RORs). When the lower limit of the 95% CI for the ROR is greater than 1 and the number of AE reports is≥3, it indicates that the preferred term (PT) may be a posit

SUBMITTER: Wang J 

PROVIDER: S-EPMC11487851 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature